Diabetes Mellitus Clinical Trial
Official title:
Point-of-care Health Literacy and Activation Information to Improve Diabetes Care
This hybrid effectiveness/implementation trial will be conducted in two phases over four years. In Phase 1, the investigators will evaluate the process of implementing a collaborative, diabetes goal-setting intervention (Empowering Patients in Chronic Care [EPIC]) personalized to self-reported patient activation and functional health literacy (FHL) levels into routine primary care practices. In Phase 2, the investigators will conduct a randomized, clinical trial to compare the effectiveness of EPIC to enhanced usual care (EUC). In Phase 2, the investigators will conduct a randomized clinical trial enrolling 284 Veterans with poorly controlled diabetes defined by average hemoglobin A1c over the last six months of >= 8% to receive EPIC or enhanced usual care (EUC). Consented subjects will be allocated evenly between EPIC and EUC. EPIC consists of six 1-hour group sessions focusing on 1) Your Health, Your Values, 2) Diabetes ABCs, 3) Setting Goals and Making Action Plans, 4) Communication with Your Health Care Provider, 5) Staying Committed to Your Goals, and 6) Reviewing and Planning for the Future. After each group session, a one-on-one session between a designated PACT member and patient participants will focus on collaborative goal-setting. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility. Study measurements using self-reported questionnaires and blood tests to assess blood sugar control will be obtained at baseline, post-intervention, and post-six month maintenance period.
Project Background: Diabetes mellitus is a highly prevalent chronic condition, affecting one
in four Veterans who use the Veterans Affairs (VA) health care system. Self-management skills
are critical for controlling diabetes and reducing its cardiovascular sequela. Providing
diabetic patients with effective self-management training and support can be challenging due
to time constraints at primary care encounters and limited clinician training with behavior
change. The investigators have previously demonstrated that a group-based, VA primary care
intervention to help patients set highly effective, evidence-based diabetes goals had a
positive impact on both diabetes self-efficacy and hemoglobin (Hb) A1c levels. This study
aims to evaluate the process of implementing a collaborative goal-setting intervention
personalized to patient activation and health literacy levels (i.e. Empowering Patients in
Chronic Care [EPIC]) into routine PACT care and to evaluate the effectiveness of this
intervention relative to usual care.
Project Objectives: Specific Aim 1: Assess effective processes for and costs associated with
implementing a collaborative diabetes goal-setting intervention personalized to patient
activation and FHL (i.e., EPIC) into the routine workflows of PACTs. H1: Formative measures
within the PARIHS framework (evidence, context, facilitation) will be associated with
implementation of EPIC (defined by reach, adoption, cost effectiveness, and fidelity
measures) into routine PACT care. Specific Aim 2: Evaluate the effectiveness of delivering
collaborative goal-setting personalized to patient activation and FHL on clinical (HbA1c) and
patient-centered (Diabetes Distress Scale) outcomes among eligible patients in enrolled
PACTs. H2: Patients receiving collaborative goal-setting personalized to activation and FHL
levels will have significant improvements in a) HbA1c and b) Diabetes Distress Scale levels,
respectively, at post-intervention compared with patients receiving enhanced usual care. H3:
Patients receiving collaborative goal-setting personalized to activation and FHL levels will
maintain significant improvements in a) HbA1c and b) Diabetes Distress Scale levels at
post-maintenance follow-up, respectively, compared with patients receiving enhanced usual
care.
Project Methods: In Phase 1 of the study, the investigators will implement EPIC into routine
PACT care. The investigators will conduct a mixed-methods formative evaluation that includes
33-48 key informant interviews with VA leadership, clinicians, and staff and an assessment of
organizational readiness for change. This evaluation will identify how group and one-on-one
sessions of EPIC can best be implemented into routine workflows of PACT. In Phase 2, the
investigators will conduct a randomized clinical trial enrolling 284 patients with poorly
controlled diabetes defined by average hemoglobin A1c of 8% to receive EPIC or enhanced usual
care. The patient will serve as the unit of randomization. EPIC consists of six 1-hour group
sessions focusing on 1) Your Health, Your Values, 2) Diabetes ABCs, 3) Setting Goals and
Making Action Plans, 4) Communication with Your Health Care Provider, 5) Staying Committed to
Your Goals, and 6) Reviewing and Planning for the Future. After each group session, a
one-on-one session between a designated PACT member and patient participants will focus on
collaborative goal-setting. Designated PACT members will be trained to personalize
goal-setting using patient-reported activation and health literacy data. The investigators
will collect laboratory and survey data at baseline, post-intervention, and post-maintenance
phase. The investigators will evaluate the effectiveness of personalized goal-setting
compared to enhanced usual care on clinical (e.g., hemoglobin A1c) and patient-centered
(e.g., Diabetes Distress Scale) outcomes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |